Vir Biotechnology (VIR) Interest Expenses (2018 - 2026)
Vir Biotechnology (VIR) posted Interest Expenses of $685000.0 for Q1 2026, up 3325.0% sequentially from $20000.0 in Q4 2025, and up 1493.02% YoY from $43000.0 in Q1 2025.
Vir Biotechnology (VIR) Interest Expenses (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Interest Expenses for 9 years, with the latest figure at $685000.0 in Q1 2026.
- Quarterly Interest Expenses rose 1493.02% year-over-year to $685000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $685000.0 (up 1493.02% YoY) and the FY2025 annual result came in at $527.1 million, up 16.26% from the prior year.
- Interest Expenses rose to $685000.0 in Q1 2026 per VIR's latest filing, from $20000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $453.4 million in Q4 2024 and troughed at $12000.0 in Q1 2024.
- A 5-year average of $97.9 million and a median of $1.1 million in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2025 and 2026: Interest Expenses plunged 100.0% in 2025, then surged 1493.02% in 2026.
- Over 5 years, Interest Expenses stood at $204.6 million in 2022, then surged by 74.4% to $356.8 million in 2023, then rose by 27.06% to $453.4 million in 2024, then slumped by 100.0% to $20000.0 in 2025, then surged by 3325.0% to $685000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $685000.0, $20000.0, and $67000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 1.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71 Mn |
| Jun 30, 2026 | 1.71 Mn |
| Mar 31, 2026 | 685,000.00 |
| Mar 31, 2026 | 685,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | 67,000.00 |
| Sep 30, 2025 | 67,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | 453.39 Mn |
| Dec 31, 2024 | 453.39 Mn |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.25 Mn |
| Mar 31, 2024 | 12,000.00 |
| Mar 31, 2024 | 12,000.00 |